Integrated Filing — IndAS



General information about company
Scrip Code 530239
NSE Symbol SUVEN
MSEI Symbol NOTLISTED
ISIN INE495B01038
Name of company SUVEN LIFE SCIENCES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 13-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented
Start date and time of board meeting 13-Aug-2025   11:30:00
End date and time of board meeting 13-Aug-2025   12:30:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 18667000
Other income 5998000
Total income 24665000
2 Expenses
(a) Cost of materials consumed 0
(b) Purchases of stock-in-trade 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0
(d) Employee benefit expense 59756000
(e) Finance costs 0
(f) Depreciation, depletion and amortisation expense 13684000
(f) Other Expenses
1 R & D Expenses 414884000 414884000
2 Other Expenses 51510000 51510000
Total other expenses 466394000
Total expenses 539834000
3 Total profit before exceptional items and tax -515169000
4 Exceptional items 0
5 Total profit before tax -515169000
6 Tax expense
7 Current tax 0
8 Deferred tax 0
9 Total tax expenses 0
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations -515169000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period -515169000
17 Other comprehensive income net of taxes -512000
18 Total Comprehensive Income for the period -515681000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0
Total profit or loss, attributable to non-controlling interests 0
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0
21 Details of equity share capital
Paid-up equity share capital 218074000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.36
Diluted earnings (loss) per share from continuing operations -2.36
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.36
Diluted earnings (loss) per share from continuing and discontinued operations -2.36
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1)tThe above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13, 2025. The results for the quarter ended June 30, 2025 has been reviewed by our statutory auditors. n2)t2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. n3)t3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. n4)tThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. n5)tESOP: For the quarter ended June 2025, the Company recognized an employee benefit expense (EBP) of Rs. 27.38 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of June 2025 amounts to Rs.154.83 lakhs. During the quarter, out of 2,21,800 options under the 1st tranche, 1,93,500 options were exercised and the Company received Rs. 106.43 lakhs pursuant to the exercise of employee stock options under its SLSL ESOP 2020 scheme. As of the reporting date, the equity shares corresponding to these exercised options had not yet been allotted. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees until 06-May-2027. n6)tPreferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. nEach warrant is convertible into one equity share of face value Rs.1 at an exercise price of Rs.134 per share, within a period of 18 months from the date of allotment. nAs per the terms of issue: n1. 25% of the warrant price is payable at the time of allotment. n2. The balance 75% is payable upon exercise of the warrant, prior to allotment of equity shares. nParticularsttttttAmount in Lakhs n25% upfront received from 23 allotteestt21,441.00 nBalance 75% received from 2 allotteestt7,724.93 nTotal money received as on 30th June 2025tt29,165.93 n7)tThe figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 150000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 362000
5 Total Other comprehensive income -512000